John P Bilezikian1, Maria Luisa Brandi, Richard Eastell, Shonni J Silverberg, Robert Udelsman, Claudio Marcocci, John T Potts. 1. Columbia University College of Physicians & Surgeons (J.P.B., S.J.S.), New York, New York 10032; University of Florence (M.L.B.), 50121 Florence, Italy; University of Sheffield (R.E.), Sheffield S5 7AU, United Kingdom; Yale University School of Medicine (R.U.), New Haven, Connecticut 06510; University of Pisa (C.M.), 56124 Pisa Italy; and Massachusetts General Hospital (J.T.P.), Boston, Massachusetts 02114.
Abstract
OBJECTIVE: Asymptomatic primary hyperparathyroidism (PHPT) is routinely encountered in clinical practices of endocrinology throughout the world. This report distills an update of current information about diagnostics, clinical features, and management of this disease into a set of revised guidelines. PARTICIPANTS: Participants, representing an international constituency, with interest and expertise in various facets of asymptomatic PHPT constituted four Workshop Panels that developed key questions to be addressed. They then convened in an open 3-day conference September 19-21, 2013, in Florence, Italy, when a series of presentations and discussions addressed these questions. A smaller subcommittee, the Expert Panel, then met in closed session to reach an evidence-based consensus on how to address the questions and data that were aired in the open forum. EVIDENCE: Preceding the conference, each question was addressed by a relevant, extensive literature search. All presentations and deliberations of the Workshop Panels and the Expert Panel were based upon the latest information gleaned from this literature search. CONSENSUS PROCESS: The expert panel considered all the evidence provided by the individual Workshop Panels and then came to consensus. CONCLUSION: In view of new findings since the last International Workshop on the Management of Asymptomatic PHPT, guidelines for management have been revised. The revised guidelines include: 1) recommendations for more extensive evaluation of the skeletal and renal systems; 2) skeletal and/or renal involvement as determined by further evaluation to become part of the guidelines for surgery; and 3) more specific guidelines for monitoring those who do not meet guidelines for parathyroid surgery. These guidelines should help endocrinologists and surgeons caring for patients with PHPT. A blueprint for future research is proposed to foster additional investigation into issues that remain uncertain or controversial.
OBJECTIVE: Asymptomatic primary hyperparathyroidism (PHPT) is routinely encountered in clinical practices of endocrinology throughout the world. This report distills an update of current information about diagnostics, clinical features, and management of this disease into a set of revised guidelines. PARTICIPANTS: Participants, representing an international constituency, with interest and expertise in various facets of asymptomatic PHPT constituted four Workshop Panels that developed key questions to be addressed. They then convened in an open 3-day conference September 19-21, 2013, in Florence, Italy, when a series of presentations and discussions addressed these questions. A smaller subcommittee, the Expert Panel, then met in closed session to reach an evidence-based consensus on how to address the questions and data that were aired in the open forum. EVIDENCE: Preceding the conference, each question was addressed by a relevant, extensive literature search. All presentations and deliberations of the Workshop Panels and the Expert Panel were based upon the latest information gleaned from this literature search. CONSENSUS PROCESS: The expert panel considered all the evidence provided by the individual Workshop Panels and then came to consensus. CONCLUSION: In view of new findings since the last International Workshop on the Management of Asymptomatic PHPT, guidelines for management have been revised. The revised guidelines include: 1) recommendations for more extensive evaluation of the skeletal and renal systems; 2) skeletal and/or renal involvement as determined by further evaluation to become part of the guidelines for surgery; and 3) more specific guidelines for monitoring those who do not meet guidelines for parathyroid surgery. These guidelines should help endocrinologists and surgeons caring for patients with PHPT. A blueprint for future research is proposed to foster additional investigation into issues that remain uncertain or controversial.
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Andrew Grey; Jenny Lucas; Anne Horne; Greg Gamble; James S Davidson; Ian R Reid Journal: J Clin Endocrinol Metab Date: 2005-01-11 Impact factor: 5.958
Authors: Mishaela R Rubin; John P Bilezikian; Donald J McMahon; Thomas Jacobs; Elizabeth Shane; Ethel Siris; Julia Udesky; Shonni J Silverberg Journal: J Clin Endocrinol Metab Date: 2008-06-10 Impact factor: 5.958
Authors: Robert Udelsman; Göran Åkerström; Carlo Biagini; Quan-Yang Duh; Paolo Miccoli; Bruno Niederle; Francesco Tonelli Journal: J Clin Endocrinol Metab Date: 2014-08-27 Impact factor: 5.958
Authors: Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian Journal: J Clin Endocrinol Metab Date: 2014-08-27 Impact factor: 5.958
Authors: A Catharine Ross; JoAnn E Manson; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; Susan T Mayne; Clifford J Rosen; Sue A Shapses Journal: J Clin Endocrinol Metab Date: 2010-11-29 Impact factor: 5.958
Authors: Richard Eastell; Maria Luisa Brandi; Aline G Costa; Pierre D'Amour; Dolores M Shoback; Rajesh V Thakker Journal: J Clin Endocrinol Metab Date: 2014-08-27 Impact factor: 5.958
Authors: Jesús Villar-Del-Moral; João Capela-Costa; Antonio Jiménez-García; Antonio Sitges-Serra; Daniel Casanova-Rituerto; José Rocha; Juan Manuel Martos-Martínez; Aitor de la Quintana-Basarrate; Jorge Rosa-Santos; Xavier Guirao-Garriga; José Miguel Bravo-de-Lifante; Óscar Vidal-Pérez; Antonio Moral-Duarte; José Polónia Journal: Langenbecks Arch Surg Date: 2015-12-19 Impact factor: 3.445
Authors: Arnoldo Piccardo; Gianluca Bottoni; Luis Alejandro Boccalatte; Chiara Camponovo; Martina Musumeci; Lorenzo Bacigalupo; Carlos Collaud; Martina Ugolini; Francesco Fiz; Pierpaolo Trimboli Journal: Endocrine Date: 2021-06-25 Impact factor: 3.633
Authors: N Singh Ospina; S Maraka; R Rodriguez-Gutierrez; A E Espinosa de Ycaza; S Jasim; M Gionfriddo; A Castaneda-Guarderas; J P Brito; A Al Nofal; P Erwin; R Wermers; V Montori Journal: Osteoporos Int Date: 2016-08-25 Impact factor: 4.507